T-Cell Acute Lymphoblastic Leukemia

Asparaginase Global Market Report 2022: Rising Incidences of Leukemia and Increasing Usage Application Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Pharmaceutical, Health, Oncology, Biomedical engineering, Leukemia, Transport, Growth, Population, Ammonia, Escherichia coli, Degenerative disease, CAGR, Asparaginase, Research, Food industry, Acute leukemia, R, Geography, Industry, Incidence, Nanomedicine, Food, T-Cell Acute Lymphoblastic Leukemia, Lymphoma, Allergy, COVID-19, Lymphoproliferative disorders, Pet, Fine chemical, Pharmaceutical industry

The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.

Key Points: 
  • The global asparaginase market is expected to grow from US$ 564.01 million in 2021 to US$ 1,575.62 million by 2028.
  • The rising incidence of leukemia and the significant growth in the pharmaceutical and food industry are the major factors boosting the market.
  • Thus, an increasing population is contributing to the expansion in the food and pharmaceutical industries, driving the global asparaginase market.
  • The increasing demand for E. coli asparaginase in the cancer treatment and food processing industry promotes the growth of the global asparaginase market.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022
People, Adenoid cystic carcinoma, Safety, Quality of life, Patient, Physician, Oncology, Abdominal wall, Nasdaq, Multiple myeloma, PR, ESMO, Aggressive fibromatosis, Treatment, ACC, Head, Organ dysfunction, European Society for Medical Oncology, RECIST, Pivotal, Plantar fibromatosis, FDA, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, MM, AYLA, DOR, Royal Marsden Hospital, QOL, Progression-free survival, GLOBE, Congress, Therapy, Incidence, Doctor of Philosophy, MRI, Cancer, ORR, T-ALL, PFS, Chronic pain, Recurrence, Pharmaceutical industry, Medical imaging, Public relations, Notch, Part

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
MM, Adenoid cystic carcinoma, Therapy, Plantar fibromatosis, T-ALL, FDA, Patient, Multiple myeloma, Pivotal, ACC, Novartis, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, Cancer, Pharmaceutical industry, Notch

A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.

Key Points: 
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations.

Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

Retrieved on: 
Wednesday, March 9, 2022
TNBC, Multiple myeloma, Plantar fibromatosis, Novartis, Patient, Therapy, FDA, T-ALL, Cancer, Pivotal, ACC, MM, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, Adenoid cystic carcinoma, Pharmaceutical industry, Notch

A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.

Key Points: 
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.
  • For more information, visit www.ayalapharma.com .

Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies

Retrieved on: 
Tuesday, January 11, 2022
Medicine, CLL, Research, T-Cell Acute Lymphoblastic Leukemia, SAN, Private Securities Litigation Reform Act, Genome, AML, Standard of care, Leukemia, U.S. Securities and Exchange Commission, Karyotype, Hospital, Hospital Insurance and Diagnostic Services Act, OGM, Cancer, Hannover Medical School, COVID-19, Adoption, Adult, Neoplasm, University Hospitals Cleveland Medical Center, Lymphatic system, Chromothripsis, Company, Method, Doctor of Philosophy, Blood, Annual report, Chronic lymphocytic leukemia, Forward-looking statement, Patient, Biology, All of Us (initiative), Genomics, Solution, Lineagen, Malignancy, Software, Workflow, FACMG, NGS, Lymphocytosis, Marker beacon, ALL, GLOBE, MLPA, Bone marrow, Autism, Acute myeloid leukemia, Security (finance), Medical imaging, Vaccine, Medical device, FISH, Quest Diagnostics

Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.

Key Points: 
  • Ten presentations from leading researchers across North America and Europe showcased the utility of OGM for hematologic malignancies at 2022 Symposium.
  • These researchers also shared examples of novel variants of potential clinical importance discovered with OGM that were undetected with other methods.
  • OGM revealed novel genetic aberrations in B-cell Chronic Lymphocytic Leukemia (B-CLL) and Acute Lymphoblastic Leukemias (ALL).
  • OGM detected more clinically relevant variants across a wide range of hematologic malignancies including acute myeloid leukemia (AML).

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Thursday, January 6, 2022
Pivotal, Novartis, Therapy, AYLA, T-ALL, Patient, T-Cell Acute Lymphoblastic Leukemia, MM, Cancer, Multiple myeloma, TNBC, Conference, Neoplasm, ACC, Adenoid cystic carcinoma, FDA, GLOBE, Nasdaq, Plantar fibromatosis, Pharmaceutical industry, Notch

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website, beginning at 7:00 AM ET on Monday, January 10, 2022.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 15, 2021
BCMA, Safety, Cancer, T-Cell Acute Lymphoblastic Leukemia, T-ALL, Partial, TNBC, European Society for Medical Oncology, Novartis, Clinical trial, Plantar fibromatosis, Area studies, ACC, D, MM, Treatment, ESMO, Gene expression, Adenoid cystic carcinoma, Temple of Israel (Wilmington, North Carolina), Doctor of Philosophy, Patient, Neoplasm, Company, Research, GLOBE, Therapy, Ongo, PDX, Multiple myeloma, Pivotal, Oncology, Nasdaq, AYLA, FDA, Current, Adult, Pharmaceutical industry

Recent Business Highlights and Upcoming Milestones:

Key Points: 
  • Recent Business Highlights and Upcoming Milestones:
    Published Two Case Studies Highlighting Clinical Activity of AL101 in Desmoid Tumors in Current Oncology: In September 2021, Ayala published two case studies of adult patients with desmoid tumors treated with AL101.
  • Collaboration Revenue: Collaboration revenue was $0.6 million for the third quarter of 2021, as compared to $0.7 million for the same period in 2020.
  • G&A Expenses: General and administrative expenses were $2.2million for the third quarter of 2021, compared to $1.9 million for the same period in 2020.
  • Net Loss: Net loss was $9.8million for the third quarter of 2021, resulting in a basic and diluted net loss per share of $0.68.

Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 10, 2021
Cancer, T-Cell Acute Lymphoblastic Leukemia, T-ALL, TNBC, Novartis, NASDAQ, Plantar fibromatosis, ACC, MM, GMT, Patient, Neoplasm, Conference, Ayala, GLOBE, Event, Therapy, Multiple myeloma, Webcast, Adenoid cystic carcinoma, AYLA, FDA, Pharmaceutical industry

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET).
  • A live webcast of the fireside chat may be accessed by visiting the Events & Presentations section of Ayalas website at ir.ayalapharma.com .
  • An archived replay of the webcast will be available on the website for approximately 90 days following the presentations.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Retrieved on: 
Thursday, September 23, 2021
People, T-Cell Acute Lymphoblastic Leukemia, Recurrence, ACC, Private Securities Litigation Reform Act, Quality, Growth, Safety, Aggressive fibromatosis, Adenoid cystic carcinoma, SEC, Confidentiality, T-ALL, PR, U.S. Securities and Exchange Commission, TNBC, Abdominal wall, Adult, Incidence, BMS, Organ dysfunction, PFS, Clinical trial, Current Oncology, Neoplasm, Annual report, Therapy, AYLA, NASDAQ, Plantar fibromatosis, FDA, Cancer, Multiple myeloma, ORR, MM, QOL, GLOBE, Chronic pain, MRI, Novartis, Risk, Doctor of Philosophy, Patient, Adolescence, Ownership, Head, Pivotal, COVID-19, DOR, Research, Quality of life, Pharmaceutical industry, Medical imaging

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.

Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC

Retrieved on: 
Thursday, September 16, 2021
Patient, Adenoid cystic carcinoma, T-Cell Acute Lymphoblastic Leukemia, FGFR, Hepatotoxicity, Malignancy, Plantar fibromatosis, Doctor of Philosophy, Neoplasm, Trae tha Truth, Exocrine gland, Research, Phase II, U.S. Securities and Exchange Commission, Oncology, Risk, HDAC, Confidentiality, Ownership, Lead, Pivotal, Private Securities Litigation Reform Act, RECIST, Gene expression, Annual report, Therapy, NASDAQ, Growth, COVID-19, GLOBE, Fast track (FDA), Notch 1, Cancer, PDX, Incidence, T-ALL, FDA, AES, AYLA, MM, HIV disease progression rates, Bristol Myers Squibb, Safety, ACC, Death, Recurrence, SEC, Seizure, Novartis, TNBC, GSI, Metastasis, Clinical trial, Disease, Multiple myeloma, Diarrhea, Pharmaceutical industry, Medical imaging, Health insurance

REHOVOT, Israel and WILMINGTON, Del., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch-activating mutations. The data is being presented at the 2021 ESMO Virtual Congress as an ePoster. In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.

Key Points: 
  • In a separate ePoster presentation, Ayala presented new preclinical results evaluating the potential of AL101 in combination with approved cancer therapies for dual targeting of ACC tumours.
  • R/M ACC remains a significant area of unmet need, and I am encouraged by the preliminary results that AL101 monotherapy has demonstrated to-date.
  • The preliminary safety and efficacy data from the 6mg cohort of our ongoing ACCURACY trial of AL101 highlights a favourable profile.
  • Preliminary Safety and Efficacy Data from 6mg Cohort of ACCURACY Phase 2 Trial:
    Ayala presented new preliminary 6mg data from its ongoing ACCURACY Phase 2 clinical trial evaluating the safety and efficacy of AL101 monotherapy for the treatment of patients with R/M ACC harboring Notch-activating mutations.